Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | RHEB | Q15382 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305772 | 0.87 | NR4A2 (0.49) | GPR84NR4A2ALDH1A1IDO1RHEB | |
| SCHEMBL3144513 | 0.87 | GPR84 (0.46) | GPR84NR4A2ALDH1A1IDO1RHEB | |
| SCHEMBL6409572 | 0.80 | GPR84 (0.49) | GPR84IDO1DAOHTR2A | |
| SCHEMBL29051233 | 0.79 | GPR84 (0.55) | GPR84NR4A2ALDH1A1IDO1RHEB | |
| SCHEMBL14527902 | 0.77 | NR4A2 (0.55) | GPR84NR4A2ALDH1A1IDO1RHEB | |
| SCHEMBL28753980 | 0.77 | GPR84 (0.49) | GPR84NR4A2ALDH1A1IDO1RHEB | |
| SCHEMBL9300868 | 0.77 | GPR84 (0.49) | GPR84NR4A2ALDH1A1IDO1RHEB | |
| SCHEMBL9299192 | 0.76 | NR4A2 (0.42) | GPR84NR4A2ALDH1A1IDO1DYRK1A | |
| SCHEMBL1853697 | 0.75 | SLC22A6 (0.54) | GPR84NR4A2ALDH1A1 | |
| SCHEMBL9300871 | 0.74 | SLC22A6 (0.62) | GPR84NR4A2ALDH1A1IDO1RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733317-A2 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MedImmune, LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3169407-B1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12492240-B2 | Neutralizing anti-influenza A antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-12487180-B2 | Device and methods for quantifying analytes introduction | Life Technologies Corporation (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250302952-A1 | METHOD OF TREATING INFLUENZA A | MEDIMMUNE, LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250263470-A1 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | MEDIMMUNE LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12357692-B2 | Method of treating influenza A | MEDIMMUNE, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4565237-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA | Chimerix, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12325740-B2 | Neutralizing anti-influenza B antibodies and uses thereof | MEDIMMUNE, LLC (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250152728-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-15 | — | — | US | disclosed |
| WO-2004042347-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040038306-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2004-02-26 | — | — | US | disclosed |
| EP-1334205-A1 | METHOD FOR IDENTIFYING LISTERIA MONOCYTOGENES AND CULTURE MEDIUM | Biomerieux S.A. (FR) | 2003-08-13 | — | — | EP | disclosed |
| US-20030073149-A1 | Antibody complexes and methods for immunolabeling | Life Technologies Corporation | 2003-04-17 | — | — | US | disclosed |
| WO-2003030817-A2 | ANTIBODY COMPLEXES AND METHODS FOR IMMUNOLABELING | MOLECULAR PROBES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002040705-A1 | METHOD FOR IDENTIFYING LISTERIA MONOCYTOGENES AND CULTURE MEDIUM | BIOMERIEUX S.A. (FR) | 2002-05-23 | — | — | WO | disclosed |
| EP-0775215-B1 | CHEMILUMINESCENCE ASSAYS BASED ON INDOXYL SUBSTRATES OR THIOINDOXYL SUBSTRATES | MEDILITE DIAGNOSTIKA (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-0775215-A1 | CHEMILUMINESCENCE ASSAYS BASED ON INDOXYL SUBSTRATES, THIOINDOXYL SUBSTRATES AND OTHER SUBSTRATES | MEDILITE DIAGNOSTIKA (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5589328-A | CHEMICAL INTERMEDIATES OR METABOLITES FOR IMMUNOASSAY | MEDILITE DIAGNOSTIKA | 1996-12-31 | — | — | US | disclosed |
| WO-1996004400-A1 | CHEMILUMINESCENCE ASSAYS BASED ON INDOXYL SUBSTRATES, THIOINDOXYL SUBSTRATES AND OTHER SUBSTRATES | MEDILITE DIAGNOSTIKA (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | PAICS, EPCAM, SQLE | GPR84 1022/4885NR4A2 2643/4885ALDH1A1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.